Compare VYGR & CMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | CMRC |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | 1079 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 211.3M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | CMRC |
|---|---|---|
| Price | $3.95 | $2.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.00 | $4.88 |
| AVG Volume (30 Days) | ★ 624.9K | 530.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $34.04 | $5.11 |
| Revenue Next Year | $7.92 | $4.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $2.41 |
| 52 Week High | $5.55 | $5.55 |
| Indicator | VYGR | CMRC |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 34.98 |
| Support Level | $3.72 | $2.43 |
| Resistance Level | $4.30 | $3.13 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 55.45 | 8.73 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.